title: Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects.
abstract: OBJECTIVE
  Several postmortem studies have reported a decreased density of serotonin 5-HT2 receptors in the prefrontal cortex in schizophrenia. The purpose of this study was to investigate this in patients with schizophrenia by means of [18F]setoperone and positron emission tomography (PET) imaging.
  
  
  METHODS
  Thirteen neuroleptic-free patients with schizophrenia, 10 of whom were also neuroleptic-naive, were compared with a group of 26 normal subjects in the same age range. The density of 5-HT2 receptors was assessed with the use of [18F]setoperone and PET in standardized cortical regions of interest.
  
  
  RESULTS
  Increasing age was associated with similar declines in 5-HT2 receptors in all cortical regions in the patient group and in the normal comparison group. After control for the effect of age, there was no statistically significant difference between the patients and the comparison subjects in 5-HT2 receptor density in any of the cortical regions.
  
  
  CONCLUSIONS
  This study failed to find the decrease in 5-HT2 receptors reported in postmortem studies of schizophrenia. The study had the power to detect a decrease of 25% or more in 5-HT2 receptors, which was anticipated on the basis of the previous postmortem studies. Thus, a primary serotonergic abnormality in schizophrenia, if one exists, is either small or unlikely to be at the level of the 5-HT2 receptors. This finding does not rule out a therapeutic role for 5-HT2 antagonists in schizophrenia, but it does suggest that the therapeutic contribution is likely to be an indirect one.
authors.affiliation: The Clarke Institute of Psychiatry, Department of Psychiatry, University of Toronto, ON, Canada.
authors.forename: R
authors.initials: R
authors.lastname: Lewis
authors.forename: S
authors.initials: S
authors.lastname: Kapur
authors.forename: C
authors.initials: C
authors.lastname: Jones
authors.forename: J
authors.initials: J
authors.lastname: DaSilva
authors.forename: G M
authors.initials: GM
authors.lastname: Brown
authors.forename: A A
authors.initials: AA
authors.lastname: Wilson
authors.forename: S
authors.initials: S
authors.lastname: Houle
authors.forename: R B
authors.initials: RB
authors.lastname: Zipursky
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use; D001923:Brain Chemistry; D002540:Cerebral Cortex / Q000737:chemistry / Q000000981:diagnostic imaging; D003287:Contrast Media; D005462:Fluorine Radioisotopes; D006801:Humans; D017397:Prefrontal Cortex / Q000737:chemistry* / Q000000981:diagnostic imaging; D011744:Pyrimidinones; D011985:Receptors, Serotonin / Q000032:analysis*; D012559:Schizophrenia / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy; D014055:Tomography, Emission-Computed
chemical_list: D014150:Antipsychotic Agents; D003287:Contrast Media; D005462:Fluorine Radioisotopes; D011744:Pyrimidinones; D011985:Receptors, Serotonin; C045359:setoperone